Indications for RIOMET ER:
Adjunct to diet and exercise in type 2 diabetes.
Take with the evening meal. ≥17yrs: initially 500mg (5mL) once daily; may increase in increments of 500mg at 1-week intervals; max 2g (20mL) once daily. If glycemic control not achieved with 2g (20mL) once daily, consider giving 1g (10mL) twice daily. If higher doses required, switch to metformin HCl immediate-release at total daily doses up to 2.55g (25.5mL) given in divided daily doses. Switching from metformin HCl immediate-release: give same total daily dose; max 2g (20mL) once daily.
<10yrs: not established. Take with the evening meal. ≥10yrs: initially 500mg (5mL) once daily; may increase in increments of 500mg at 1-week intervals; max 2g (20mL) once daily.
RIOMET ER Contraindications:
Severe renal impairment (eGFR <30mL/min/1.73m2). Metabolic acidosis, diabetic ketoacidosis, with or without coma.
RIOMET ER Warnings/Precautions:
Increased risk of metformin-associated lactic acidosis in renal or hepatic impairment, concomitant use of certain drugs (eg, cationic drugs), ≥65yrs of age, undergoing radiological contrast study, surgery and other procedures, hypoxic states, and excessive alcohol intake; discontinue if lactic acidosis occurs. Discontinue at time of, or prior to intravascular iodinated contrast imaging in patients with eGFR 30–60mL/min/1.73m2, history of hepatic impairment, alcoholism, heart failure, or will be given intra-arterial contrast; reevaluate eGFR 48hrs after procedure and restart therapy if renally stable. Suspend therapy if dehydration occurs or before surgery. Avoid if clinical or lab evidence of hepatic disease. Assess renal function prior to starting and periodically thereafter; more frequently in elderly. If eGFR between 30–<45mL/min/1.73m2: do not initiate. Elderly, debilitated, uncompensated strenuous exercise, malnourished or deficient caloric intake, adrenal or pituitary insufficiency, or alcohol intoxication: increased risk of hypoglycemia. Monitor hematology annually and Vit. B12 every 2–3yrs. Resumption of premenopausal ovulation in anovulatory patients may occur (may result in unintended pregnancy). Pregnancy. Nursing mothers.
RIOMET ER Classification:
RIOMET ER Interactions:
Increased risk of lactic acidosis with topiramate, other carbonic anhydrase inhibitors (eg, zonisamide, acetazolamide, dichlorphenamide); monitor. Concomitant cationic drugs that interfere with renal tubular transport systems (eg, ranolazine, vandetanib, dolutegravir, cimetidine) may increase metformin levels; consider benefits/risks. Avoid excessive alcohol intake (potentiates effects of metformin on lactate). Diuretics, steroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, sympathomimetics, calcium channel blockers, isoniazid, nicotinic acid, others may cause hyperglycemia; monitor. May need lower dose of concomitant sulfonylurea or insulin to reduce risk of hypoglycemia.
Diarrhea, nausea, vomiting, flatulence, asthenia, indigestion, abdominal discomfort, headache; Vit. B12 deficiency; rare: lactic acidosis (may be fatal).
Soln—118mL, 473mL; ER susp—473mL (w. diluent, dosing cup)